"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA EXPANDED THE INDICATIONS OF REGORAFENIB (STIVARGA) TO INCLUDE THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

FDA EXPANDED THE INDICATIONS OF REGORAFENIB (STIVARGA) TO INCLUDE THE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC)

27 Apr 2017 2:44 PM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration expanded the indications of regorafenib (Stivarga) to include the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software